Group 1 - The core viewpoint of the news is that Lexin Medical (300562) has officially launched its large model application focused on cardiovascular and cerebrovascular disease risk assessment, with successful pilot results [1] - The company emphasizes that it cannot predict the specific impact of this business on future performance and advises investors to be cautious of risks [1] - This development reflects the company's innovative layout in the field of AI digital chronic disease management, which may positively influence market sentiment [1] Group 2 - In the recent stock performance, Lexin Medical's stock price showed noticeable fluctuations over the past seven trading days, closing at 14.65 yuan on February 13, a slight increase of 0.21% from 14.62 yuan on February 6 [2] - The stock experienced a volatility of 5.75% during this period, with a peak price of 15.03 yuan on February 11 [2] - In terms of capital flow, on February 11, there was a net outflow of 4.4588 million yuan from main funds, while speculative funds saw a net inflow of 4.9387 million yuan, indicating short-term capital divergence [2]

Core Viewpoint - The company has made progress in developing a large model application focused on cardiovascular diseases, which includes risk assessment capabilities and has undergone successful pilot testing [2] Group 1 - The large model application is primarily aimed at cardiovascular disease [2] - The application has been launched and has completed relevant pilot tests with positive results [2] - The company is unable to predict the future impact of this business on its performance [2]